Enclomiphene Citrate Side Effects: Rare but Serious Adverse Events

What Is Enclomiphene Citrate and Why Does the Safety Profile Matter?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. Unlike racemic clomiphene, which contains roughly equal parts enclomiphene (trans) and zuclomiphene (cis), the isolated enclomiphene molecule has a shorter half-life of approximately 10 hours compared to zuclomiphene's estimated 30-plus days. That pharmacokinetic difference was the original rationale for believing enclomiphene would carry fewer cumulative side effects. Repros Therapeutics pursued FDA approval under the trade name Androxal, reaching Phase III trials before the FDA issued a Complete Response Letter in 2016.

The shorter half-life does reduce the risk of drug accumulation, yet it does not eliminate class-related SERM risks. Clinicians prescribing off-label or compounded enclomiphene need a clear-eyed view of what rare adverse events look like, how to screen for them, and when to stop therapy.

Enclomiphene vs. Racemic Clomiphene: Why the Distinction Matters for Safety

Racemic clomiphene has decades of post-market safety data. A 2019 analysis of the FDA Adverse Event Reporting System (FAERS) identified thromboembolic events, visual complaints, and hepatic signals across thousands of clomiphene reports. Because enclomiphene is still compounded rather than approved, its FAERS footprint is smaller, but the pharmacological mechanism is identical enough that clinicians should treat class-level warnings as applicable.

Regulatory Background

Repros Therapeutics completed three key trials (ZA-304, ZA-301, and ZA-302) in men with secondary hypogonadism. In ZA-304 (N=289), 25 mg enclomiphene daily normalized serum testosterone to 300 ng/dL or above in a significantly higher proportion of men than topical testosterone gel, while preserving sperm production. Those trials, however, were powered for efficacy, not for detecting rare adverse events with incidence below 1 in 500.

Thromboembolic Events: The Most Clinically Significant Rare Risk

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents the most consequential rare adverse event associated with the SERM class. Enclomiphene raises endogenous estrogen as a downstream consequence of elevated LH and FSH, and estrogen is a well-established promoter of coagulation factor synthesis.

Mechanism of Prothrombotic Effect

Estrogens upregulate hepatic production of clotting factors VII, VIII, X, and fibrinogen while simultaneously suppressing protein S, a natural anticoagulant. The FDA labeling for clomiphene citrate explicitly warns of thromboembolism as a rare but serious adverse reaction. Because enclomiphene shares the same receptor pharmacology, the same prothrombotic pathway applies.

Observed Incidence and Risk Stratification

In the ZA-304 and ZA-301 trials, no fatal thromboembolic events were reported, but the combined trial population of fewer than 700 men and durations of 26 weeks are insufficient to rule out low-frequency VTE. A large pharmacovigilance study in women using clomiphene for ovulation induction found a VTE incidence of approximately 0.4 per 1,000 treatment cycles, a figure that provides rough context for SERM-class risk even though the population differs.

Prescribers should perform pre-treatment thrombophilia screening in any patient with:

• Personal or family history of DVT or PE
• Factor V Leiden or prothrombin gene mutation
• Antiphospholipid antibody syndrome
• Immobility, recent surgery, or active malignancy
• Obesity with BMI above 35

Clinical Presentation and When to Stop Therapy

Any new unilateral leg swelling, pleuritic chest pain, or unexplained dyspnea in a patient taking enclomiphene should prompt immediate discontinuation and urgent evaluation. Restarting after a confirmed VTE event is contraindicated. Hematology consultation is appropriate before any rechallenge in patients with provoked VTE and a correctable risk factor.

Visual Disturbances: Low Incidence, High Consequence

Visual adverse events occur in roughly 1.5 to 2 percent of patients on racemic clomiphene and are considered a class effect. The reduced cumulative exposure from enclomiphene's shorter half-life may lower risk, but does not eliminate it.

Types of Visual Adverse Events

Reported visual symptoms associated with SERM therapy include:

• Blurred vision (most common, typically transient)
• Phosphenes (flashes of light or floaters)
• Visual field defects (scotomas, including central scotoma)
• Diplopia (double vision, rare)
• Prolonged after-images (palinopsia)

The FDA's clomiphene labeling notes that visual disturbances may be irreversible if the drug is continued after symptom onset, stating: "Patients should be warned that these visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual."

Pathophysiology

The exact mechanism is debated. Leading hypotheses include direct estrogen receptor-mediated effects on retinal pigment epithelium and clomiphene isomer accumulation in ocular tissues. Case reports published in ophthalmology literature document persistent phosphene activity and electroretinogram changes in patients who used clomiphene for more than six weeks. Because zuclomiphene accumulates far longer than enclomiphene, shorter-duration use of the pure trans-isomer may carry lower retinal risk, though head-to-head ophthalmic comparison data do not yet exist.

Prescriber Action Steps

Any new visual symptom warrants same-day ophthalmologic evaluation and immediate discontinuation. The drug must not be restarted until a full slit-lamp and visual field examination rules out retinal or optic nerve pathology.

Hepatotoxicity: A Signal Worth Watching

Clinically significant liver injury from enclomiphene is rare, but the signal exists in the post-market literature for racemic clomiphene and in isolated FAERS case narratives for enclomiphene-containing compounds.

Known Hepatic Adverse Events with Clomiphene

A case series in the Journal of Clinical Gastroenterology documented cholestatic hepatitis in three women using clomiphene, with bilirubin elevations up to 12 mg/dL and normalization within eight weeks of drug discontinuation. The pattern was consistent with drug-induced liver injury (DILI) with a cholestatic phenotype.

What to Monitor

Baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) are recommended before starting enclomiphene in any patient with pre-existing hepatic risk factors, including:

• Known non-alcoholic fatty liver disease (NAFLD)
• Alcohol use disorder
• Prior DILI from any medication
• Concurrent anabolic steroid use

Repeat LFTs at 8 to 12 weeks of therapy, then every 6 months during maintenance. An ALT elevation above three times the upper limit of normal (ULN) without symptoms, or above two times ULN with jaundice or right upper quadrant pain, warrants discontinuation and hepatology referral.

Interaction Risk

Enclomiphene is metabolized via CYP3A4. Concurrent use of strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may raise plasma levels and increase hepatic exposure. The NIH LiverTox database classifies clomiphene as a "possible" cause of clinically apparent liver injury, a designation that should be applied cautiously to enclomiphene until independent hepatic safety data accumulate.

Psychiatric Adverse Events: Depression, Mood Dysregulation, and Suicidality

This is perhaps the least-discussed serious adverse event category for enclomiphene. SERM-class drugs modulate estrogen receptors in the limbic system and prefrontal cortex, and the neuropsychiatric consequences can be severe in susceptible individuals.

Mechanism of Mood Effects

Estrogen receptors in the hypothalamus and amygdala regulate serotonin transporter expression and dopaminergic tone. Enclomiphene's partial agonist/antagonist activity at these central receptors may precipitate dysphoria, anxiety, or emotional lability in patients with underlying mood vulnerability. Animal studies published in Neuropsychopharmacology demonstrate that SERM-class compounds alter serotonin receptor binding in limbic regions in a dose-dependent fashion.

Clinical Reports

In the ZA-301 and ZA-304 trial safety tables, mood-related adverse events were reported in fewer than 3 percent of enclomiphene participants and did not differ significantly from placebo. ZA-304 data, published in the Journal of Clinical Endocrinology and Metabolism, showed an adverse event discontinuation rate of 4.2% across active treatment arms. However, trial populations systematically exclude patients with active psychiatric diagnoses, meaning real-world incidence in men with comorbid depression or anxiety may be higher.

Suicidality: Rare But Documented

Post-market reports to FAERS for clomiphene include cases of suicidal ideation, one completed suicide, and multiple hospitalizations for acute psychiatric decompensation. Because enclomiphene shares the pharmacological mechanism, a warning is warranted. Patients with a PHQ-9 score of 10 or above or active psychiatric treatment require psychiatry co-management before enclomiphene initiation.

Monitoring Protocol

Use the PHQ-9 and GAD-7 at baseline, at week 4, and at week 12. Any new-onset suicidal ideation (PHQ-9 item 9 score of 1 or above) requires same-day clinical contact, drug hold, and mental health referral.

Cardiovascular Considerations Beyond Thromboembolism

Enclomiphene's effects on the cardiovascular system extend beyond VTE risk. Changes in lipid metabolism, blood pressure, and cardiac rhythm have been documented at the class level.

Lipid Profile Changes

SERMs can produce paradoxical effects on lipid panels. Raloxifene, another SERM, lowers LDL but raises triglycerides in some patients. A secondary analysis of the ZA-302 trial reported modest changes in total cholesterol across both enclomiphene doses without reaching statistical significance (P<0.10 for both comparisons vs. Placebo), suggesting the lipid effect of enclomiphene at 12.5 to 25 mg daily is small but real. Patients with pre-existing hypertriglyceridemia should have a fasting lipid panel at 12 weeks.

Blood Pressure

Testosterone elevation may cause modest fluid retention and blood pressure elevation. In ZA-304, systolic blood pressure changes between arms were not clinically significant, but individual patients with pre-existing hypertension should have blood pressure checked at every visit during the first 3 months of therapy.

Atrial Fibrillation

No trial has reported an elevated incidence of atrial fibrillation with enclomiphene specifically. The FDA FAERS dashboard does include isolated AF reports for clomiphene, and given shared pharmacology, clinicians should note any palpitations or irregular heartbeat and pursue ECG evaluation before attributing them to other causes.

Ovarian Hyperstimulation Syndrome (OHSS) Equivalent in Men: Testicular Over-Stimulation

OHSS is a well-recognized complication of gonadotropin stimulation in women. In men, excessive LH and FSH stimulation from enclomiphene can produce a clinical analog: testicular pain, supra-physiological testosterone elevations, and polycythemia.

Polycythemia and Erythrocytosis

Testosterone above the physiological range (greater than 1,000 ng/dL) stimulates erythropoietin and raises hematocrit. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends withholding testosterone therapy if hematocrit exceeds 54 percent. The same threshold should apply to enclomiphene-driven testosterone elevations. Polycythemia raises viscosity and VTE risk, compounding the direct SERM thrombogenic effect.

Testicular Pain and Enlargement

LH surges driven by enclomiphene can cause testicular discomfort. This is not malignant but warrants ultrasound evaluation to exclude torsion or other structural pathology if pain is acute or severe.

Drug Interactions That Amplify Risk

Several commonly co-prescribed agents interact with enclomiphene in ways that could increase the severity of rare adverse events.

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors raise enclomiphene plasma concentrations. Patients on HIV protease inhibitors, azole antifungals, or macrolide antibiotics should have dose reduction considered and liver enzymes checked more frequently.

Anticoagulants

For patients who have an independent indication for anticoagulation (atrial fibrillation, prior VTE), the baseline thromboembolic risk is already elevated. Enclomiphene adds an additional estrogen-mediated procoagulant drive. The combination requires a shared decision-making conversation with hematology or vascular medicine.

Other SERMs and Hormonal Agents

Combining enclomiphene with tamoxifen, raloxifene, or aromatase inhibitors is not supported by trial data and may produce unpredictable receptor competition. The Endocrine Society guideline notes that combination SERM therapy lacks evidence for superiority over monotherapy in hypogonadal men.

What the Phase III Trial Data Actually Tell Us About Rare Event Frequency

The three key Repros trials (ZA-301, ZA-302, ZA-304) enrolled a combined population of fewer than 800 men, with treatment durations of 12 to 26 weeks. Basic statistical power calculations illustrate a hard limit: to detect an adverse event with a true incidence of 1 in 500 (0.2%) with 80% power, a trial needs approximately 1,600 participants per arm. None of the enclomiphene trials approached that size.

ZA-304 (N=289) showed that 25 mg enclomiphene produced a mean serum testosterone of 412 ng/dL at week 26 versus 360 ng/dL for testosterone gel, with comparable safety profiles over the study period. "The results demonstrate that enclomiphene citrate can normalize testosterone levels while maintaining spermatogenesis, a profile that differs from exogenous testosterone," the ZA-304 authors concluded, but they explicitly noted the trial was not powered to assess rare adverse events.

This statistical gap is the most important clinical reality for prescribers: absence of observed rare events in these trials does not mean those events do not occur. Post-market surveillance through FAERS, case reports, and registry data will define enclomiphene's true rare adverse event profile over the next decade.

Prescriber Checklist: Pre-Treatment Screening for Serious Risk Factors

Before initiating enclomiphene citrate, every prescriber should document the following:

1. Thrombophilia screen: personal or family VTE history, Factor V Leiden status if relevant
2. Ophthalmologic baseline: document any pre-existing visual symptoms
3. LFTs and metabolic panel: ALT, AST, ALP, total bilirubin, CBC with hematocrit
4. Psychiatric screen: PHQ-9 and GAD-7 scores documented
5. Lipid panel: fasting total cholesterol, LDL, HDL, triglycerides
6. Blood pressure: measured and documented
7. Current medications: full reconciliation for CYP3A4 interactions and anticoagulant co-use
8. Hormone panel: total testosterone, LH, FSH, estradiol to confirm secondary hypogonadism

Monitoring at weeks 4, 8, 12, and then every 6 months should include repeat testosterone, LH, FSH, CBC with hematocrit, and a brief clinical review of visual symptoms and mood.

Stopping Rules: When to Discontinue Enclomiphene Immediately

Any of the following findings require same-day drug discontinuation:

• New visual disturbance of any type (pending ophthalmology evaluation)
• Hematocrit above 54 percent
• ALT or AST above 3x ULN (or 2x ULN with jaundice)
• Confirmed DVT or PE
• Active suicidal ideation (PHQ-9 item 9 score of 1 or above)
• Serum testosterone consistently above 1,100 ng/dL despite dose reduction

Do not restart enclomiphene after confirmed VTE, persistent retinal visual field defect, or hepatotoxicity with jaundice without a formal multi-disciplinary assessment.